Modulation of TRAIL-Induced Apoptosis by Moringa Oleifera Seed Extract and Docetaxel in LNCaP Cells

Prostate cancer remains one of the most common cancers affecting men globally, and researchers are actively searching for plant-derived compounds that might work alongside existing chemotherapy drugs. This study tested whether an extract made from Moringa oleifera seeds could kill prostate cancer cells in the laboratory, and whether combining it with docetaxel — a standard chemotherapy drug — produced a stronger effect than either substance alone. Working with LNCaP cells, a well-established human prostate cancer cell line, the researchers found that the moringa seed extract reduced cancer cell survival in a way that depended on both the dose given and the time of exposure. Docetaxel produced the same pattern independently. When a lower dose of the moringa extract was paired with a mid-range dose of docetaxel, the combination killed more cells than would be expected if the two substances simply added their effects together — a result the authors describe as potentiation. Both the extract and docetaxel also raised levels of TRAIL, a protein the body uses to trigger a self-destruction process in abnormal cells called apoptosis. Higher TRAIL levels suggest the moringa extract may be nudging cancer cells toward programmed death rather than simply poisoning them. The findings matter because they point toward a possible mechanism — TRAIL up-regulation — through which moringa seed compounds might complement chemotherapy. However, this is entirely laboratory work on cultured cells, so the distance between these results and any clinical application is very large. No animal or human data are presented, and the study does not identify which specific compounds in the extract are responsible for the observed effects.